Relevant bibliographies by topics / Metastatic carcinoma

Academic literature on the topic 'Metastatic carcinoma'

Author: Grafiati
Published: 4 June 2021
Last updated: 19 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Metastatic carcinoma.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Metastatic carcinoma"

1

Cheng, Shaun Kian Hong, and Khoon Leong Chuah. "Metastatic Renal Cell Carcinoma to the Pancreas: A Review." Archives of Pathology & Laboratory Medicine 140, no. 6 (June 1, 2016): 598–602. http://dx.doi.org/10.5858/arpa.2015-0135-rs.

Full text
Abstract:
The pancreas is an unusual site for tumor metastasis, accounting for only 2% to 5% of all malignancies affecting the pancreas. The more common metastases affecting the pancreas include renal cell carcinomas, melanomas, colorectal carcinomas, breast carcinomas, and sarcomas. Although pancreatic involvement by nonrenal malignancies indicates widespread systemic disease, metastatic renal cell carcinoma to the pancreas often represents an isolated event and is thus amenable to surgical resection, which is associated with long-term survival. As such, it is important to accurately diagnose pancreatic involvement by metastatic renal cell carcinoma on histology, especially given that renal cell carcinoma metastasis may manifest more than a decade after its initial presentation and diagnosis. In this review, we discuss the clinicopathologic findings of isolated renal cell carcinoma metastases of the pancreas, with special emphasis on separating metastatic renal cell carcinoma and its various differential diagnoses in the pancreas.
APA, Harvard, Vancouver, ISO, and other styles
2

Sadr, AH, S. de Kerviler, and N. Kang. "Cutaneous basal cell carcinoma with endobronchial metastasis." Annals of The Royal College of Surgeons of England 96, no. 7 (October 2014): e20-e21. http://dx.doi.org/10.1308/003588414x13946184902244.

Full text
Abstract:
Although basal cell carcinoma is a very common malignancy, metastasis from this tumour is extremely rare. For this reason, many plastic surgeons, dermatologists and physicians dealing with skin malignancies consider this as a locally invasive malignancy. We present a rare case of metastatic basal cell carcinoma manifested as a bronchial tumour. This case highlights the fact that despite basal cell carcinoma’s local invasive potential, the possibility of distant metastasis still exists and clinicians should therefore be cautious about interpreting extracutaneous symptoms. Chest physicians should always consider the possibility of this rare tumour in the lungs in patients with a history of large basal cell carcinomas in the head and neck region.
APA, Harvard, Vancouver, ISO, and other styles
3

ÇEÇEN, Ayşe, Esra KAVAZ, and Seda GÜN. "A rare case: Renal cell carcinoma metastasis to lower lip." Journal of Experimental and Clinical Medicine 38, no. 3 (April 23, 2021): 396–97. http://dx.doi.org/10.52142/omujecm.38.3.38.

Full text
Abstract:
Approximately 15% of renal cell carcinomas metastasize to the head and neck region. Here in, we report a rare case report of a patient who underwent nephrectomy for renal cell carcinoma (RCC) ten years ago and presented with metastatic renal cell carcinoma on her lower lip. A 65-year-old woman presented with a rapidly growing mass on the lower lip. Pathology report resulted in renal cell carcinoma metastasis. Although metastatic renal cell carcinoma to the head and neck is uncommon, metastasis should be considered in the differential diagnosis of a rapidly growing vascular lesion in the head and neck area of patients with renal cell carcinoma.
APA, Harvard, Vancouver, ISO, and other styles
4

Wahyuni, Siska Dwiyantie, Sri Suryanti, Hasrayati Agustina, and Bethy Suryawathy Hernowo. "The Association of Clinicopathological Features with Metastatic Status in Infiltrative Urothelial Carcinoma of Bladder." Journal of Drug Delivery and Therapeutics 10, no. 6-s (December 18, 2020): 99–102. http://dx.doi.org/10.22270/jddt.v10i6-s.4647.

Full text
Abstract:
Background: Infiltrative urothelial carcinoma of bladder is an aggressive variant of bladder carcinoma. Most of the patients in their first encounter with doctors are diagnosed with advanced stages and many has metastasized. Metastasis is a process of malignant tumor cells migrating from its primary tumor location to other organs or sites inside the body via blood circulation or lymphatic system. Metastasis process is responsible for 90% cancer deaths compared to the primary tumor itself, infiltrative urothelial carcinoma of bladder. To reduce mortality, knowledge of the clinicopathological characteristics associated with metastasis is needed. Method: Research material used was clinical data and paraffin block from patients with metastatic and non-metastatic infiltrative urothelial carcinoma of bladder. Clinical data taken from Central Medical Record Installation and Urology Medical Record Installation Padjadjaran University/ Dr. Hasan Sadikin Hospital Bandung, Indonesia. Paraffin blocks were obtained from operations at Hasan Sadikin Hospital Bandung, Indonesia.Total data sample obtained were 40 samples, 20 samples are metastatic and another 20 are non-metastatic samples. Clinicopathological parameters included in the analysis were age, sex and pathalogical T stage. Result: Pathalogical T stage have associations with metastatic status with significant result with p value=0.035 (p<0.005). Conclusion: Pathalogical T stage was associated with the metastatic status of Infiltrative urothelial carcinoma of bladder and may play important roles during the metastatic process. Thus, it can be used as a predictor factor for the infiltrative urothelial carcinoma of bladder. Keywords: infiltrative urothelial carcinoma of bladder, metastastic, pathalogical T stage
APA, Harvard, Vancouver, ISO, and other styles
5

ÇEÇEN, Ayşe, Esra KAVAZ, and Seda GÜN. "The clinical and prognostic value of the neutrophil lymphocyte ratio, the platelet lymphocyte ratio and mean platelet volume in tinnitus patients." Journal of Experimental and Clinical Medicine 38, no. 3 (April 23, 2021): 251–54. http://dx.doi.org/10.52142/omujecm.38.3.8.

Full text
Abstract:
Approximately 15% of renal cell carcinomas metastasize to the head and neck region. Here in, we report a rare case report of a patient who underwent nephrectomy for renal cell carcinoma (RCC) ten years ago and presented with metastatic renal cell carcinoma on her lower lip. A 65-year-old woman presented with a rapidly growing mass on the lower lip. Pathology report resulted in renal cell carcinoma metastasis. Although metastatic renal cell carcinoma to the head and neck is uncommon, metastasis should be considered in the differential diagnosis of a rapidly growing vascular lesion in the head and neck area of patients with renal cell carcinoma.
APA, Harvard, Vancouver, ISO, and other styles
6

Liang, Huasheng, Yuhua Zhong, Zuojie Luo, Yu Huang, Huade Lin, Min Luo, Song Zhan, Kaiqing Xie, Yan Ma, and Qingdi Quentin Li. "Assessment of Biomarkers for Clinical Diagnosis of Papillary Thyroid Carcinoma with Distant Metastasis." International Journal of Biological Markers 25, no. 1 (January 2010): 38–45. http://dx.doi.org/10.1177/172460081002500106.

Full text
Abstract:
Early diagnosis and treatment of thyroid cancers are critical for better prognosis and better survival rates. The purpose of this study was to identify potential diagnostic markers for papillary thyroid carcinomas with distant metastasis. Fifty-eight papillary thyroid tumor specimens (27 papillary thyroid carcinomas with distant metastasis and 31 without metastasis) were examined, and protein expression of pituitary tumor-transforming gene (PTTG), E-cadherin, p27kip1, vascular endothelial growth factor (VEGF)-C, metalloproteinase (MMP) 2, MMP9, chemokine receptor CXCR4, and basic fibroblast growth factor (bFGF) in these tumors was assessed by immunohistochemistry. The clinicopathological variables with diagnostic significance were determined by multivariate analysis, and their diagnostic values were evaluated by ROC curve analysis. PTTG, VEGF-C, MMP2, MMP9, CXCR4, and bFGF were overexpressed in metastatic papillary thyroid carcinomas, whereas p27kip1 expression was elevated only in carcinomas lacking metastasis. Multiple-factor binary ordinal logistic regression analysis revealed that PTTG, VEGF-C, MMP2, and bFGF were independently related to biological metastatic behavior in thyroid tumors, suggesting their potential use as biomarkers. ROC curve analysis showed that among these four proteins, VEGF-C and bFGF were the best diagnostic biomarkers. A VEGF-C and bFGF cluster was the most useful factor for the differential diagnosis between metastatic and non-metastatic papillary thyroid cancers. Thus, the combined use of VEGF-C and bFGF as biomarkers may improve the diagnostic accuracy of papillary thyroid carcinoma and may be useful in multimodal screening programs for the clinical diagnosis of papillary thyroid carcinoma and early detection of papillary thyroid carcinoma with distant metastasis.
APA, Harvard, Vancouver, ISO, and other styles
7

Shanbhag, Nandan. "Metastatic colorectal carcinoma: Response to panitumumab." Journal of the Bahrain Medical Society 30, no. 1 (March 20, 2018): 5–8. http://dx.doi.org/10.26715/jbms.1_01032018.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Nunez, D. A., C. G. C. Sutherland, and R. K. Sood. "Breast metastasis from a pharyngeal carcinoma." Journal of Laryngology & Otology 103, no. 2 (February 1989): 227–28. http://dx.doi.org/10.1017/s0022215100108540.

Full text
Abstract:
AbstractThe reported incidence of metastatic disease in head and neck cancer is increasing. The most common site of metastatic involvement in squamous carcinoma of the head and neck is the lung followed by liver, mediastinal nodes and bone. The breast is rarely infiltrated by metastatic disease, 2 per cent or less of clinically detected breast lumps being of nonmammary origin, most frequently malignant melanoma, lymphoma/leukaemia and primary lung carcinoma.A 73-year-old female presented with a primary posterior pharyngeal wall squamous carcinoma and bilateral enlarged neck nodes. She developed an isolated breast metastasis while receiving palliative radiotherapy and died seven months after presentation.Clinically detected breast metastasis in head and neck squamous cell carcinoma was first documented by Toombs and Kalisher in 1977. This is the first report of such a case originating in the posterior pharyngeal wall. The prognosis is invariably poor.
APA, Harvard, Vancouver, ISO, and other styles
9

Xu, K., Q. Ye, L. Han, and M. Zhong. "A Comparative Analysis of Immunohistochemical Profile of Primary and Metastatic Endometrial Endometrioid Carcinoma." American Journal of Clinical Pathology 154, Supplement_1 (October 2020): S32—S33. http://dx.doi.org/10.1093/ajcp/aqaa161.066.

Full text
Abstract:
Abstract Introduction/Objective Beta catenin plays an important role in cancer tumorigenesis and have been found to be associated with metastasis in a variety of tumors. Analyzing TCGA data, we found that 30% of endometrial endometrioid carcinoma cases have beta-catenin mutations. We hypothesize that beta-catenin mutation may be associated with metastasis of endometrial endometrioid carcinoma. ER and PR expression was also compared to determine any changes after metastasis. Methods Retrospective institutional review of all endometrial endometrioid carcinoma (192 cases) between 2011 to 2018 was performed, including 149 cases of FIGO grade I, 38 cases of FIGO grade II and 5 cases of FIGO grade III. 19 cases with paired primary and metastatic specimen were identified. Immunohistochemistry staining (IHC) was carried out for ER, PR and beta-catenin. Results Median patient age was 56 years. The most common metastatic site was vagina, accounting for 68% of metastasis (14/19), followed by bladder (3/19), lung (2/19) and rectum (1/19). The primary and metastatic carcinoma of all 19 cases exhibit very similar morphology. All of those cases were positive and concordant for ER and PR in primary and metastatic endometrioid carcinoma. On the other hand, nuclear beta-catenin staining caused by mutation was positive in 5 metastatic carcinoma but not in primary carcinoma. Conclusion IHC expression of ER and PR remains unchanged between primary and metastatic carcinoma, demonstrating the reliability of ER and PR to confirm the origin of metastatic carcinoma. 26% of the metastatic carcinoma (5/19) exhibit nuclear beta-catenin staining but not in primary carcinoma, suggesting the possible role of beta-catenin in metastasis of endometrial endometrioid carcinoma.
APA, Harvard, Vancouver, ISO, and other styles
10

Tickoo, Satish K., Anastassios G. Pittas, Michael Adler, Melissa Fazzari, Steven M. Larson, Richard J. Robbins, and Juan Rosai. "Bone Metastases From Thyroid Carcinoma." Archives of Pathology & Laboratory Medicine 124, no. 10 (October 1, 2000): 1440–47. http://dx.doi.org/10.5858/2000-124-1440-bmftc.

Full text
Abstract:
Abstract Context.—Only limited information exists on the pathologic aspects of thyroid carcinomas with bone metastases, most large studies having concentrated mainly on their clinical features. Objective.—To study in detail the morphologic features of thyroid carcinomas with skeletal metastases. Design.—Seventy-nine cases of thyroid carcinoma with bone metastases treated at Memorial Sloan-Kettering Cancer Center, New York, NY, between 1964 and 1998 were investigated, with emphasis on the pathology of the primary and/or metastatic tumors and comparison of the morphologic features of the tumors at both the sites, wherever possible. The tumors were also compared for various clinical parameters. Results.—The cohort consisted of 22 papillary, 17 follicular, 16 insular, 10 anaplastic, 9 Hürthle cell, and 5 medullary carcinomas. Of these cases, 68% had poorly differentiated or undifferentiated features in the primary and/or metastatic tumors. The metastatic tumors were better differentiated than the primary in one third of the cases (6 of 18). Only one case showed a less differentiated metastasis. The overall 5- and 10-year survival probabilities after the bone metastases were 29% and 13%, respectively (Kaplan-Meier method). Although both the tumor type and differentiation seemed to affect survivals after bone metastasis (P = .007 and .012, respectively) (log-rank test), this was primarily due to the much worse prognosis in the cases of anaplastic and medullary carcinoma. Cases of Hürthle cell carcinoma showed the longest median survival. There was no significant difference in survival among patients up to or older than 45 years at the time of metastases (P = .31). Conclusions.—Most thyroid carcinomas with bone metastases are of papillary type, and most have poorly differentiated or undifferentiated features. The influence of the microscopic tumor type and tumor differentiation on survival after bone metastasis primarily appears to be due to the much worse prognosis among anaplastic and medullary carcinomas. Age at diagnosis of bone metastases does not influence survivals.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Metastatic carcinoma"

1

Nordman, Ina IC Clinical School St Vincent's Hospital Faculty of Medicine UNSW. "Surrogate endpoints of survival in metastatic carcinoma." Publisher:University of New South Wales. Clinical School - St Vincent's Hospital, 2008. http://handle.unsw.edu.au/1959.4/42791.

Full text
Abstract:
In most randomised controlled trials (RCTs), a large number of patients need to be followed over many years, for the clinical benefit of the drug to be accurately quantified (1). Using an early proxy, or a surrogate endpoint, in place of the direct endpoint of overall survival (OS) could theoretically shorten the duration of RCTs and minimise the exposure of patients to ineffective or toxic treatments (2, 3). This thesis examined the relationship between surrogate endpoints and OS in metastatic colorectal cancer (CRC), advanced non-small cell lung cancer (NSCLC) and metastatic breast cancer (MBC). A review of the literature identified 144 RCTs in metastatic CRC, 189 in advanced NSCLC and 133 in MBC. The publications were generally of poor quality with incomplete reporting on many key variables, making comparisons between studies difficult. The introduction of the CONSORT statement was associated with improvements in the quality of reporting. For CRC (337 arms), NSCLC (429 arms) and MBC (290 arms) there were strong relationships between OS and progression free survival (PFS), time to progression (TTP), disease control rate (DCR), response rate (RR) and partial response (PR). Correlation was also demonstrated between OS and complete response (CR) in CRC and duration of response (DOR) in MBC. However, while strong relationships were found, the proportion of variance explained by the models was small. Prediction bands constructed to determine the surrogate threshold effect size indicated that large improvements in the surrogate endpoints were needed to predict overall survival gains. PFS and TTP showed the most promise as surrogates. The gain in PFS and TTP required to predict a significant gain in overall survival was between 1.2 and 7.0 months and 1.8 and 7.7 months respectively, depending on trial size and tumour type. DCR was a better potential predictor of OS than RR. The results of this study could be used to design future clinical trials with particular reference to the selection of surrogate endpoint and trial size.
APA, Harvard, Vancouver, ISO, and other styles
2

Lee, Yee-ki Carol. "Effect of dietary fatty acids on metastatic hepatocellular carcinoma /." Click to view the E-thesis via HKUTO, 2007. http://sunzi.lib.hku.hk/hkuto/record/B39707349.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Malek, Joël. "Genetic alterations of the metastatic lesions in ovarian carcinoma." Thesis, Paris 11, 2011. http://www.theses.fr/2011PA11T109.

Full text
Abstract:
Le cancer de l’ovaire est le cancer gynécologique avec la plus grande mortalité due à un diagnostique tardif au stade de maladie extensive péritonéale. Malgré les progrès de la chirurgie radicale et de la chimiothérapie les récurrences abdominales demeurent la cause la plus fréquente de mortalité. Il existe peu d’études de la maladie métastatique péritonéale. Notre hypothèse de travail est que les différences entre la maladie métastatique et la tumeur primaire sont primordiales dans la survenue d’une maladie résiduelle ou récurrente. Nous avons utilisé une approche exhaustive comprenant des études du transcriptome, des variations du nombre de copie (VNC) et des sequençages des exomes pour caractériser les différences entre lésions primaires, métastases péritonéales et métastases lymphatiques.Résultats: Notre étude démontre que les VNC varient de façon significative entre la tumeur primaire et la métastase peritonéale. Les différences d’expressions géniques bien que mineures permettent de retrouver les voies de signalisation primordiales pour le développement des métastases. Le séquençage des exomes montre très peu de différences en terme de polymorphisme. Par ailleurs la majorité des polymorphismes présents dans les métastases se retrouvent à une faible fréquence dans la tumeur primaire de façon concordante avec la théorie clonale. Conclusion: L’ensemble des résultats montre la possibilité d’une origine clonale de la maladie métastatique des cancers de l’ovaire comportant la majorité des anomalies au niveau des variations du nombre de copie. L’intégration de ces données permettrait d’optimiser les thérapeutiques ciblées
Ovarian cancer is the most deadly gynecological cancer. The high rate of mortality is due to the large tumor burden with extensive metastatic lesion of the abdominal cavity. There are few studies on genetic alterations and their consequences in peritoneal metastatic tumors when compared to their matched ovarian primary tumors. Our hypothesis is that differences between the metastatic and primary lesions might be the cause of residual disease and, most importantly may have a role in post-chemotherapeutic recurrences. Methods: We conducted integrated genomics analysis on matched primary and metastatic tumors from 9 patients. In the papers presented here we analyze genome-wide Copy Number Variations (CNVs) using SNP Arrays targeting peritoneal metastasis differences, Gene expression differences using Microarrays also targeting peritoneal metastasis differences, and for some patients, Single Nucleotide Polymorphisms (SNPs) in genes through Exome sequencing.Results: Here we show that CNVs vary significantly between primary and metastatic tumors and include genes that have been considered potential chemotherapeutic targets based on primary tumor only data. Gene expression differences, while minor, showed highly statistically significant enrichment of genes in ovarian cancer critical pathways. In agreement with findings in other cancers, exome sequencing data revealed very few SNP differences of which most metastasis enriched SNPs were present at very low levels in the primary tumor. The results presented here should allow better design of therapies to target residual ovarian cancer disease
APA, Harvard, Vancouver, ISO, and other styles
4

Bartrolí, Comellas Mariona. "Prognostic markers and therapeutic targets for metastatic renal cell carcinoma." Doctoral thesis, Universitat de Barcelona, 2018. http://hdl.handle.net/10803/664198.

Full text
Abstract:
Targeting cancer metastasis has gained considerable importance in the recent years when aiming to increase patients’ overall survival. In Renal Cell Carcinoma (RCC), the discovery of metastatic biomarkers and targets is still required, as most patients present metastatic disease at the time of diagnosis. Therefore, the aim of this thesis is the discovery of new biomarkers and targets of metastatic RCC using two variants of a patient-derived orthoxenograft (PDOX) animal model of clear cell RCC (ccRCC). Indeed, PDOX models have recently gained significant relevance for studying the progression of cancer and metastasis, due to their better mimicking of the histology, the metastatic capacity and treatment responses of human cancers. To this purpose, previous results had sequenced the two variants of this PDOX model, both at DNA and at RNA level, and had performed a FISH analysis. Firstly, Carboxypeptidase E (CPE), which was one of the highest expressed genes in the metastatic variant, has demonstrated to play a role in invasion when it is secreted to the medium, even though its overexpression alone is not sufficient to generate metastasis in vivo. In addition, it has showed a clear association to ccRCC and an inverse correlation with the overall survival of these patients. Secondly, we have studied two molecules of the coagulation pathway due to its relevance as one of the most upregulated pathways at RNA level. On the one hand, Factor XIII (FXIII or F13) has shown to be related to CPE in vivo, despite the overexpression of both molecules is not sufficient to develop all the metastatic cascade. However, it also affects the overall survival of ccRCC patients, highlighting these two molecules as possible biomarkers for this type of cancer. On the other hand, Coagulation Factor II Thrombin Receptor (F2R or PAR1) has demonstrated to play a role in metastasis, since its inhibition reduces both the early and late phases of this process. With the use of F2R inhibitors and the clinical association of the coagulation pathway to worse prognosis, this thesis opens new opportunities for the treatment of metastasis and cancer malignization. In summary, we have discovered new metastatic biomarkers and targets which, together with further validations, especially in the clinical setting, are proposed to be useful for RCC patients in the future.
Recentment, l’estudi de la metàstasi ha guanyat importància amb l’objectiu d’augmentar la supervivència dels pacients amb càncer. En el càncer renal (RCC), el descobriment de biomarcadors metastàtics i dianes terapèutiques és necessari degut a que la majoria de pacients presenten metàstasi en el moment del diagnòstic. L’objectiu d’aquesta tesi ha estat el descobriment de nous biomarcadors i dianes terapèutiques pel càncer renal metastàtic a través de dues variants d’un model animal orthoxenograft (PDOX) de RCC de cèl·lula clara (ccRCC). Els models PDOX han guanyat molta importància en l’estudi de la progressió del càncer i la metàstasi, ja que mimetitzen la histologia, la capacitat metastàtica i la resposta als tractaments. Prèviament, s’havien seqüenciat les dues variants d’aquest model PDOX tant a nivell de DNA com de RNA, juntament amb un anàlisi FISH. En primer lloc, la Carbxoxipeptidasa E (CPE), un dels gens més expressats en la variant metastàtica, ha demostrat ser important en la invasió quan és secretada al medi, tot i no ser suficient per generar metàstasi in vivo. A més, s’ha associat amb el ccRCC i anti-correlacionat amb la supervivència d’aquests pacients. En segon lloc, hem estudiat dues molècules de la cascada de coagulació, una de les més alterades en nivells de RNA. Hem demostrat que el Factor XIII (FXIII o F13) està relacionat amb CPE in vivo, malgrat que l’expressió de les dues molècules no és suficient per a que es desenvolupi la metàstasi. Tot i així, el F13 afecta la supervivència de pacients amb ccRCC, suggerint aquestes dues molècules com a possibles biomarcadors d’aquest tipus de càncer. A més, la inhibició del Receptor del Factor de Coagulació II (F2R) ha demostrat reduir les fases inicials i finals del procés metastàtic. Així doncs, l’ús d’inhibidors de F2R, juntament amb el fet que la cascada de coagulació es relaciona amb el pronòstic dels pacients, fa que aquesta tesi obri noves oportunitats per al tractament de la metàstasi i la malignització del càncer. En resum, hem descobert nous biomarcadors i dianes terapèutiques que, juntament amb futures validacions, sobretot en clínica, poden ser útils per als pacients metastàtics de ccRCC.
APA, Harvard, Vancouver, ISO, and other styles
5

Pilborough, Alice Elizabeth. "Tumour-stromal crosstalk in metastatic lymph nodes of oral squamous cell carcinoma." Thesis, University of Sheffield, 2018. http://etheses.whiterose.ac.uk/22053/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Ho, Chi-lai, and 何志禮. "Dual-tracer positron emission tomography in the evaluation ofprimary & metastatic hepatocellular carcinoma." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2010. http://hub.hku.hk/bib/B45205024.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Griffin, Ryan D. "MULTISPECTRAL CO-OCCURRENCE ANALYSIS FOR AUTOMATED TUMOR DETECTION IN METASTATIC MEDULLARY THYROID CARCINOMA." The Ohio State University, 2010. http://rave.ohiolink.edu/etdc/view?acc_num=osu1285101309.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Okuno, Tomoko. "Loss of heterozygosity on 10q23 is involved in metastatic recurrence of hepatocellular carcinoma." Kyoto University, 2011. http://hdl.handle.net/2433/142555.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Kerr, Ian Balfour. "A study of metastasis in colorectal carcinoma using DNA recombinant and molecular hybridisation techniques." Thesis, University of Edinburgh, 1989. http://hdl.handle.net/1842/19010.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Swofford, Brenen P., and Tomislav Dragovich. "Durable and Complete Response to Herceptin Monotherapy in Patients with Metastatic Gastroesophageal Cancer." KARGER, 2017. http://hdl.handle.net/10150/626424.

Full text
Abstract:
Gastroesophageal cancer is the sixth leading cause of cancer-related death worldwide. The 2 most common histologies are squamous cell carcinoma and adenocarcinoma, which has seen an increase in incidence correlating with an increase in obesity in developed countries. Gastroesophageal adenocarcinoma has a preponderance to metastasize early, making it a highly lethal cancer with a low 5-year survival rate of similar to 15-25%. Therefore, for the majority of patients, treatment focuses on palliation and prolongation of survival. Combination chemotherapy regimens, mostly platinum-based, have only modestly prolonged survival in patients with stage IV disease. Recently, it was discovered that the activation of the HER2 receptor plays an important role in a minority of adenocarcinomas of the distal esophagus and stomach. This introduced the treatment option of trastuzumab (Herceptin), a monoclonal antibody directed at the HER2 receptor, which has demonstrated improvement in overall and progression-free survival as noted in the ToGA trial. Currently, the role of Herceptin therapy beyond first-line therapy and outside of combination regimens is not well established. In this case report we review 2 cases of patients with gastroesophageal cancer, with HER2 overexpression, who achieved a robust response to trastuzumab in combination with chemotherapy and were able to maintain a durable response with maintenance trastuzumab monotherapy. (c) 2017 The Author(s) Published by S. Karger AG, Basel.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Metastatic carcinoma"

1

Warner, Ellen. Phase I - II study of vinblastine and oral cyclosporin a in metastatic renal cell carcinoma. Ottawa: National Library of Canada, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

International, Symposium on Cellular Oncology (2nd 1985 Palm Springs Calif ). Occult nodal metastasis in solid carcinomata. New York: Praeger, 1987.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Oral cancer metastasis. New York: Springer, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Hoogewoud, H. M. Hepatocellular carcinoma and liver metastases: Diagnosis and treatment. Berlin: Springer-Verlag, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

McElligott, Anthony M. The role of matrix metalloproteinases and their inhibitors, the tissue inhibitors of metalloproteinases, in renal cell carcinoma cell invasion and metastasis. [S.l: The Author], 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Surgical Treatment of Metastatic Renal Cell Carcinoma. Derman Tıbbi Yayıncılık, 2015. http://dx.doi.org/10.4328/derman.9786055121242.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

A, Stein Cy, and National Cancer Institute (U.S.). Office of Cancer Communications, eds. Suramin, an active agent in metastatic adrenocortical carcinoma. [Bethesda, Md.?]: National Cancer Institute, Office of Cancer Communications, 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Huang, William C., and Ezequiel Becher. Advanced and Metastatic Renal Cell Carcinoma an Issue of Urologic Clinics. Elsevier, 2020.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Calabrò, Fabio, and Cora N. Sternberg. Treatment of metastatic bladder cancer. Edited by James W. F. Catto. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199659579.003.0079.

Full text
Abstract:
Although bladder cancer is considered a chemosensitive malignancy, the prognosis of patients with metastatic disease is poor, with a median survival of approximately 12–14 months in good prognosis patients and with cure in only a minority. The addition of new drugs to the standard cisplatin-based regimens has not improved these outcomes. In this chapter, we highlight the role of chemotherapy and the impact of the new targeted agents in the treatment of metastatic bladder carcinoma. A better understanding of the underlying biology and the molecular patterns of urothelial bladder cancer has led to clinical investigation of several therapeutic targets. To date, these agents have yet to demonstrate an improvement in overall survival. Urothelial cancer is extremely sensitive to checkpoint inhibition with both anti PD-1 and anti PDL1 antibodies. The future seems brighter with the advent of these new therapies.
APA, Harvard, Vancouver, ISO, and other styles
10

Massey, Veta Hamblen. RELATIONSHIP BETWEEN POWERLESSNESS, HARDINESS, DIAGNOSIS, AND HOPELESSNESS IN PERSONS HOSPITALIZED FOR CHOLECYSTECTOMY OR METASTATIC CARCINOMA. 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Metastatic carcinoma"

1

Casadei, Roberto, and Marco Gambarotti. "Metastatic Carcinoma." In Atlas of Musculoskeletal Tumors and Tumorlike Lesions, 251–55. Cham: Springer International Publishing, 2013. http://dx.doi.org/10.1007/978-3-319-01748-8_55.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Nakashima, Toshiro, and Masamichi Kojiro. "Metastatic Liver Cancers." In Hepatocellular Carcinoma, 245–53. Tokyo: Springer Japan, 1987. http://dx.doi.org/10.1007/978-4-431-68334-6_16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Bacchini, Patrizia, and Franco Bertoni. "Metastatic Bone Carcinoma." In Tumors and Tumor-Like Lesions of Bone, 601–8. London: Springer London, 2015. http://dx.doi.org/10.1007/978-1-4471-6578-1_46.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Bacchini, Patrizia, and Franco Bertoni. "Metastatic Bone Carcinoma." In Tumors and Tumor-Like Lesions of Bone, 603–9. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-28315-5_49.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Tsakayannis, D. E., and Dimitrios A. Linos. "Metastatic Adrenocortical Carcinoma." In Adrenal Glands, 151–57. Berlin, Heidelberg: Springer Berlin Heidelberg, 2005. http://dx.doi.org/10.1007/3-540-26861-8_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

McGregor, Bradley A., and Guru P. Sonpavde. "Management of Metastatic Penile Cancer." In Penile Carcinoma, 125–32. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-82060-2_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Suzuki, Ayana, Mitsuyoshi Hirokawa, and Aki Tanaka. "Metastatic Renal Cell Carcinoma." In Thyroid FNA Cytology, 399–403. Singapore: Springer Singapore, 2019. http://dx.doi.org/10.1007/978-981-13-1897-9_51.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Pradhan, Tapaswani, and Sudhir Bahadur. "Metastatic Neck Disease." In Carcinoma of the Larynx and Hypopharynx, 41–61. Singapore: Springer Singapore, 2019. http://dx.doi.org/10.1007/978-981-13-3110-7_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Song, Won Hoon, and Hyeong Dong Yuk. "Treatment of Metastatic Bladder Cancer." In Management of Urothelial Carcinoma, 123–37. Singapore: Springer Singapore, 2019. http://dx.doi.org/10.1007/978-981-10-5502-7_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Powles, Tom, and Axel Bex. "Integration of Surgery in Metastatic Renal Cancer." In Renal Cell Carcinoma, 257–77. Totowa, NJ: Humana Press, 2012. http://dx.doi.org/10.1007/978-1-62703-062-5_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Metastatic carcinoma"

1

Gupta, Vivek, Amita Mishra, Namit Kalra, and Bhawna Narula. "A rare case report of incidental solitary uterine metastasis in primary invasive lobular carcinoma of breast." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685401.

Full text
Abstract:
Introduction: Infiltrating Lobular carcinoma (ILC) of the breast is second most common cancer of breast next only to Infiltrating ductal carcinoma (IDC). It has a different metastatic pattern as compared to the IDC. Breast cancer is the most frequent primary site which spreads to gynaecologic organs. Case Presentation: A 40 yrs old Iraqi lady presented as a diagnosed case of lobular carcinoma of left breast. She had already undergone a lumpectomy at Iraq a month back and now had come for completion of treatment. On metastatic workup with PETCT scan, we found a multicentric residual disease in the left breast along with some ipsilateral axillary LN with significant uptake. The concurrent CECT done showed a uterine leiomyomam also. As she was strongly hormone receptor positive, had completed her family and was having mennorhagia probably attributable to uterine fibroids. She was offered hysterectomy with B/L salpingo-oophorectomy. She was keen for breast preservation but in view of her multicentricity of disease on the left breast she was counselled for mastectomy with upfront whole breast reconstruction with TRAM flap. She underwent left modified radical mastectomy with hysterectomy with BSO and TRAM flap reconstruction. The histopathological examination revealed a multicentric, multifocal ILC, grade II with heavy nodal involvement including extracapsular extension. The leiomyoma of uterus also showed tumor deposits from lobular carcinoma breast. Conclusion: We report a very rare case of metastatic pattern of carcinoma of breast. On literature review we found that it is common for the lobular carcinomas of breast to metastasise to gynaecologic organs. Uterine corpus is a very rare site of metastasis for extragenital cancers including breast. All the patients of primary lobular carcinoma of breast should be screened for gynaecologic secondaries in the preoperative workup with high degree of suspicion.
APA, Harvard, Vancouver, ISO, and other styles
2

Singh, Gajender, Sant Parkash Kataria, and Rajeev Sen. "Carcinoma uterine cervix metastasis to the skin: A rare case report." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685280.

Full text
Abstract:
Introduction: Most common site of metastasis from carcinoma cervix is lung, liver, bone and brain. Cutaneous metastasis is rare occurrence in carcinoma cervix. Incidence reported ranges from 0.1 to 2%. Common morphological pattern of skin metastases are nodules, plaques and inflammatory telangiectatic lesions. Materials and Methods: A 68 years old postmenopausal female diagnosed as squamous cell carcinoma of cervix stage III B. She was given chemotherapy and radiotherapy and on regular follow up without no evidence of disease locally. After two years she presented with a sub cutaneous nodule of approximately 5x4 cm size just below the left scapula of one month duration. There was no similar swelling in any other region. It was rapidly increased in size and painful. The FNAC of the nodule showed metastatic from squamous cell carcinoma. PET scan showed metastases in bilateral lung and pelvic lymph node with no evidence of local disease. Excision biopsy of the nodule confirmed the diagnosis. Conclusion: Cutaneous metastases from carcinoma cervix are rare. Differential diagnoses include benign dermatitis, subcutaneous phycomycosis, and plaque like mycosis fungoides.
APA, Harvard, Vancouver, ISO, and other styles
3

Vallabhaneni, Akhil, and Jennifer W. Toth. "Metastatic Primary Airway Adenoid Cystic Carcinoma." In American Thoracic Society 2010 International Conference, May 14-19, 2010 • New Orleans. American Thoracic Society, 2010. http://dx.doi.org/10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a5893.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Mishra, Amita, Archit Pandit, Namit Kalra, and Bhawna Narula. "Primary signet ring cell mucinous carcinoma ovary: A very rare neoplasm." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685405.

Full text
Abstract:
Introduction: Mucinous ovarian carcinomas are less common than serous and endometriod type, and are more frequently confined to the ovary at the time of diagnosis. But primary signet ring cell mucinous carcinomas of the ovary are extremely rare. Case Presentation: A 40 yr old patient presented with extremely rare primary signet cell mucinous carcinoma of ovary. She presented with abdominal distension and frequency of urination for one month. She was evaluated and CECT whole abdomen was s/o large left ovarian mass. All the tumor markers were with in normal range. Laparotomy frozen section of left adnexal mass was done and was reported as malignant with sheets of signet ring cells seen. Hence complete staging laparotomy including TAH with RSO with bilateral pelvic lymph node dissection with total omentectomy with para aortic lymph node dissection. Final histopathology with IHC markers were S/O primary signet ring cell carcinoma of ovary with no extracapsular invasion, no lymph nodal involvement & no metastatic spread. Conclusion: We present a very rare case of primary signet ring cell of ovary, confined to ovary itself. On literature review only 14 cases have been reported and of them very few are malignant.
APA, Harvard, Vancouver, ISO, and other styles
5

Coutinho-Camillo, Cláudia M., Renato D. Puga, Cibele P. Nagano, Yukie Sato-Kuwabara, Felipe D'Almeida Costa, Clóvis A. Lopes Pinto, Luiz P. Kowalski, Fernando A. Soares, and Silvia V. Lourenço. "Abstract 4005: microRNA profiles in metastatic versus non-metastatic salivary mucoepidermoid carcinoma." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-4005.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Yıldız, Pınar, Sariha Buyukluoglu, and Mesut Bayraktaroğlu. "Bilateral chylothorax due to gastric carcinoma and metastatic prostate carcinoma: Case reports." In ERS International Congress 2019 abstracts. European Respiratory Society, 2019. http://dx.doi.org/10.1183/13993003.congress-2019.pa2020.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Yadav, Sushma. "Unusual clinical presentation of chriocarcinoma in young patients – Neulological meatastasis." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685389.

Full text
Abstract:
Introduction: Choriocarcinoma is a malignant trophoblastic tumor, usually of placenta and characterized by ‘early hematogenous spread’ to lungs. Choriocarcinoma of placenta is preceded by – H. Mole (50%), spontaneous abortion (20%), ectopic pregnancy (2%) and normal term pregnancy (20%-30%). It is chemosensitive tumor and even in metastatic lesion cure rate is 90%-95%. Most common site of metastasis is lung and vagina, vulva, kidney, liver, ovaries, brain and intestine. If tumor is not diagnosed and managed timely, because of its vascularity, it bleeds profusely leading to death. Cases: We encountered 2 rare cases, with age of 25 and 27 years respectively with choriocarcinoma with unusual clinical presentation. Both patients presented with neurological symptoms of brain metastasis and succumbed to death within a short span of time. In both cases histopathological report failed to detect chorio-carcinoma but b-HCG and radiological findings were suggestive of choriocarcinoma. Conclusion: If b–HCG level are unusually high with radiological findings, the patients should be considered for chemotherapy even if HPE is inconclusive. Without chemotherapy chorio-carcinoma has a rapid progression and mortality which can be prevented by early suspicion and timely management.
APA, Harvard, Vancouver, ISO, and other styles
8

Liu, Ping, Xiaomin Ren, and Lisa X. Xu. "Alternate Cooling and Heating Thermal Physical Treatment: An Effective Strategy Against MDSCs in 4T1 Mouse Mammary Carcinoma." In ASME 2012 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2012. http://dx.doi.org/10.1115/sbc2012-80229.

Full text
Abstract:
An alternate thermal physical treatment was developed to destroy tumor tissue using liquid nitrogen cooling and RF heating treatment in our pervious study. Our pervious reports had shown that anti-tumor immunity was induced by the alternate treatment. Myeloid derived suppressor cells (MDSCs) are a subset of heterogeneous, bone marrow derived hematopoietic cells that accumulate in the spleen, bone marrow, blood and tumor sites of tumor-bearing mice and cancer patients. MDSCs are one of the key suppressor cells that regulate anti-tumor immune responses in tumor-bearing hosts. MDSCs have been shown to inhibit the function of various types of cells mediating anti-tumor immunity, such as T cells, B cells, NK cells and dendritic cells. MDSCs are recruited specifically to the tumors and contribute indirectly to angiogenesis, growth and metastasis. MDSCs also exert resistance to cancer therapies, such as anti-VEGF strategies and cancer immunotherapy. Given the role of MDSCs in tumor invasion and metastasis and anti-tumor immune responses, therapeutics targeting MDSCs might offer a new strategy for cancer treatment. In this study, the therapeutic effect and MDSCs changes after the alternate cooling and heating treatment was studied using the 4T1 murine mammary carcinoma, a common animal model of human metastatic breast cancer. Due to its highly invasive and poorly immunogenic characters, the 4T1 tumor could cause death even after the primary tumor was surgically removed. The treatment was carried out when micro-metastases were well established. Comparisons were made with the results from the surgery and hyperthermia groups, respectively. The results showed that MDSCs in blood increased rapidly with time after tumor inoculation, and in 66 days, all the mice died in the control group. The statistical results indicated a significant increase in circulating MDSC numbers at different tumor growth stages. In the surgical resection group, MDSCs in blood did not decrease, but increased rapidly to a level much higher that of the control group in 39 day after tumor inoculation. In the hyperthermia group, MDSCs in blood increased rapidly with time after tumor inoculation, and in 39 day, MDSCs was up to 3 times higher than that of the control group. Mice died in 45 day after initial tumor inoculation. But in the alternate treatment group, the number of MDSCs decreased rapidly and recovered to the normal healthy level in 11 days after the treatment. No metastatic tumor could be observed in these mice, and they were in good physiological conditions as observed in the following 3 month. In conclusion, the alternate treatment was found extremely effective against MDSCs in the very aggressive and highly metastatic mouse mammary carcinoma. The good prognosis was expected in relation to the significant decrease in MDSCs and thus the relief of the immune suppression, induced by the alternate cooling and heating treatment. It could be further developed as a novel therapeutic method against metastatic tumor. On the other hand, combining the alternate treatment with other strategies, such as anti-VEGF and cancer immunotherapy, the best therapeutic effect would be achieved through synergy.
APA, Harvard, Vancouver, ISO, and other styles
9

Shah, Swati, Shveta Giri, Rupinder Sekhon, and Sudhir Rawal. "Inguinal lymphadenopathy as a presentation for ovarian cancer." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685329.

Full text
Abstract:
Ovarian carcinoma usually presents at an advanced stage with diffuse intra abdominal manifestations. Inguinal lymph node metastasis is rare event in ovarian cancer. We report 7 cases who presented with inguinal lymphadenopathy as the initial manifestation between January 2014 to January 2016. All patients underwent tru-cut biopsy from inguinal area. Morphology and IHC were suggestive of ovarian origin or female genital Tract origin. Two patients underwent primary debulking surgery while four patients were managed by neo-adjuvant chemotherapy followed by interval cytoreductive surgery owing to relatively poor performance status at presentation. One patient underwent secondary debulking in which inguinal Lymph node was positive for metastatic deposits.
APA, Harvard, Vancouver, ISO, and other styles
10

Lees, Katherine, Jamie Van Gompel, and Jeffrey Janus. "Metastatic Oropharyngeal Squamous Cell Carcinoma to the Cavernous Sinus." In 29th Annual Meeting North American Skull Base Society. Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0039-1679681.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Metastatic carcinoma"

1

Bhatia, Pardeep. Study of RANKL Expression in Metastatic Breast Carcinoma. Fort Belvoir, VA: Defense Technical Information Center, June 2003. http://dx.doi.org/10.21236/ada418749.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Bhatia, Pardeep. Study of RANKL Expression in Metastatic Breast Carcinoma. Fort Belvoir, VA: Defense Technical Information Center, June 2002. http://dx.doi.org/10.21236/ada405313.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Sahin, Aysegul A. Treatment of Metastatic Breast Carcinoma Refractory to Doxorubicin with Liposomal-Annamycin. Fort Belvoir, VA: Defense Technical Information Center, October 2001. http://dx.doi.org/10.21236/ada411291.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Sahin, Aysegul A. Treatment of Metastatic Breast Carcinoma Refactory to Doxorubicin with Liposomal-Annamycin. Fort Belvoir, VA: Defense Technical Information Center, October 1999. http://dx.doi.org/10.21236/ada391551.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Sahin, Aysegul A. Treatment of Metastatic Breast Carcinoma Refractory to Doxorubicin with Liposomal-Annamycin. Fort Belvoir, VA: Defense Technical Information Center, October 2000. http://dx.doi.org/10.21236/ada393780.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Dolan, Brian P. A Novel Therapeutic Vaccine for Metastatic Mammary Carcinoma: Focusing MHC/Peptide Complexes to Lipid Rafts. Fort Belvoir, VA: Defense Technical Information Center, May 2005. http://dx.doi.org/10.21236/ada437901.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Qian, Jiekun, Zhangwei Tong, Yannan Zhang, and Chun Chen. Immunotherapy vs platinum for advanced or metastatic thymic carcinoma: A systematic review and meta-analysis protocol. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, November 2020. http://dx.doi.org/10.37766/inplasy2020.11.0060.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Kufe, Donald. Fusions of Breast Carcinoma and Dendritic Cells as a Vaccine for the Treatment of Metastatic Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, July 2004. http://dx.doi.org/10.21236/ada429626.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Kufe, Donald W. Fusions of Breast Carcinoma and Dendritic Cells as a Vaccine for the Treatment of Metastatic Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, July 2006. http://dx.doi.org/10.21236/ada459218.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Kufe, Donald W. Fusions of Breast Carcinoma and Dendritic Cells as a Vaccine for the Treatment of Metastatic Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, July 2007. http://dx.doi.org/10.21236/ada548399.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Metastatic carcinoma' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography